Neurocritical Care News

The FDA has granted accelerated approval for Leqembi for the treatment of Alzheimer’s disease, making it the second approved Alzheimer’s treatment, the agency announced in a press release.

As the world continues to grapple with effects of the COVID-19 pandemic, individuals around the globe are still dealing with symptoms of SARS-CoV-2 infection for months, even years, after their initial infection.

Migraine has a bidirectional relationship with mental disorders such as anxiety and depression, and one may increase the risk of the other, researchers reported in Cureus.

In patients with active secondary progressive MS, hematopoietic stem cell transplants may delay disability longer than some MS medications, researchers reported in Neurology.

There was insufficient evidence of excess harm associated with off-label IV thrombolysis in patients after ischemic stroke with recent intake of a direct oral anticoagulant, researchers reported in JAMA Neurology.

A congressional investigation found the FDA’s interactions with Biogen were “atypical and failed to follow” protocol and that the two “inappropriately collaborated” on documentation before the approval of Aduhelm for Alzheimer’s disease.

The blood-based measure of neurofilament light chain was associated with the presence of neuronal injury in those with peripheral neuropathy, according to a systematic review and meta-analysis in JAMA Network Open.

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.